title: Bleeding and thrombosis risk matters: how long can we stick to the one-size-fits-all strategy of platelet inhibition?
authors: Dirk
authors: D
authors: Sibbing
authors: Lisa
authors: L
authors: Gross
authors: Martin
authors: M
authors: Orban
authors: Steffen
authors: S
authors: Massberg
mesh_terms: D054058:Acute Coronary Syndrome / Q000628:therapy*; D000077144:Clopidogrel; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D008297:Male; D062645:Percutaneous Coronary Intervention; D010879:Piperazines / Q000009:adverse effects*; D015539:Platelet Activation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D000068799:Prasugrel Hydrochloride; D013876:Thiophenes / Q000009:adverse effects*; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D013876:Thiophenes; D000077144:Clopidogrel; D000068799:Prasugrel Hydrochloride; D013988:Ticlopidine
keywords: bleeding; clopidogrel; percutaneous coronary intervention; prasugrel; stent thrombosis; therapeutic window